ArQule Downgraded to “Neutral” at Zacks (ARQL)
ArQule (NASDAQ:ARQL) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued to investors on Wednesday, Analyst Ratings.Net reports. They currently have a $2.80 price objective on the stock. Zacks‘ target price suggests a potential upside of 16.18% from the stock’s previous close.
ArQule (NASDAQ:ARQL) traded down 2.49% during mid-day trading on Wednesday, hitting $2.35. The stock had a trading volume of 108,325 shares. ArQule has a 52-week low of $1.91 and a 52-week high of $3.10. The stock’s 50-day moving average is $2.24 and its 200-day moving average is $2.36. The company’s market cap is $147.4 million.
Separately, analysts at RBC Capital cut their price target on shares of ArQule from $6.00 to $5.00 in a research note to investors on Monday, November 11th. They now have a “sector perform” rating on the stock. Five research analysts have rated the stock with a hold rating, The company presently has a consensus rating of “Hold” and an average price target of $3.26.
ArQule, Inc is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.